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Metal-based drugs that break the rules
Claire S. Allardyce and Paul J. Dyson*
Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are
applied in the majority of anticancer chemotherapeutic regimens. The success of these compounds has
biased the approaches used to discover new metal-based anticancer drugs. In this perspective we high-
light compounds that are apparently incompatible with the more classical (platinum-derived) concepts
employed in the development of metal-based anticancer drugs, with respect to both compound
design and the approaches used to validate their utility. Possible design approaches for the future are
also suggested.
Introduction
In 1967, when Rosenberg set out to investigate the eﬀect of an
electrical field on bacterial growth, he observed elongation of
the bacteria with the inhibition of cell division. Following a
series of careful studies he found that the eﬀect was not due to
the field, but to the platinum electrodes producing cis-dichloro-
diamineplatinum(II), i.e. cisplatin (Fig. 1).1 The complex was
released into the medium where it entered the cells and
formed adducts with DNA, primarily intra-strand cross-links,2
preventing replication. The discovery came at a time when
anticancer compound screening focused on small organic
molecules. It marked the entry of inorganic complexes (in the
case of cisplatin, a carbon-free compound) into the arena.
Cisplatin has gone on to revolutionize cancer treatment ren-
dering formerly fatal disease, such as testicular cancer,
largely curable.3 As a result, the intense research eﬀort that
preceded cisplatin’s discovery shifted focus to include in-
organic complexes with the objective of both widening the
spectrum of chemotherapy of cisplatin and improving its clini-
cal profile; after all, the (chance) discovery of cisplatin
suggested that some rational design could lead to improved
metal-based drugs.
Today platinum drugs (cisplatin, carboplatin and oxali-
platin – Fig. 1) are used in an estimated 50–70% of cancer
treatment regimens.4 The reason that cisplatin and its deriva-
tives are not used in all cancer treatments is that some tumour
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Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de
Lausanne (EPFL), CH-1015 Lausanne, Switzerland. E-mail: paul.dyson@epfl.ch
This journal is © The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 3201–3209 | 3201
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 5
/6
/2
01
9 
7:
57
:0
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
types are resistant at the maximum tolerable dose. Dosage is
limited by general toxicity, which manifests as severe side
eﬀects, including nausea, vomiting, loss of sensation in the
extremities and nephrotoxicity. Some important types of
cancer that are resistant to cisplatin include types of breast
cancer, the most common cancer among women in Europe,
and prostate cancer, which is the most common cancer among
men in the United States and Europe.5 In addition cisplatin is
largely inactive on colorectal cancers, which have increasing
incidences in many countries, and many late stage cancers
are also unresponsive, possibly due to epigenetic modifi-
cations.6 Other cancers can acquire cisplatin resistance during
treatment.7
Drug design concepts related to the
chemistry of the complexes
Relatively soon after the entry of cisplatin into the clinic a wide
range of related compounds were prepared and evaluated.
Neutral Pt(II) complexes with a square-planar geometry, includ-
ing two cis-coordinated leaving groups, were defined as critical
structural features for anticancer activity. As cisplatin is
administered intravenously into the bloodstream, various
transportation mechanisms have been proposed.8 Neverthe-
less, the coordination complex is believed to remain in a
neutral, unchanged state during circulation and, after entering
cells where intracellular chloride levels are lower than in
blood, exchange of one or both chloride ligands by more labile
ligands occurs thereby activating the complex. These findings
led to a further rule being defined, i.e. slow ligand exchange
rates relative to the rates of cell division processes. The rules
was deemed necessary to render the complex inactive during
transport and implies the use of mostly second and third row
transition metal ions.9
Various other rules were proposed as the mechanism of
action of clinically successful platinum complexes became
better understood and certain rules were abandoned and
replaced by other rules and concepts. It was also found that
compounds that were apparent ‘rule-breakers’ often had
highly relevant and unique anticancer properties. For example,
highly active di- and tri-nuclear cationic Pt(II) agents, in which
the metal centres are linked by flexible diamine chains, do not
contain cis-leaving groups.10 The complexes are active against
a broad spectrum of tumours, including cisplatin-resistant cell
lines, with apparently stronger DNA binding leading to these
eﬀects. The lead complex in this class of multinuclear plati-
num complexes is a trinuclear compound called triplatin tetra-
nitrate or BBR3464 (also called CT-3610, Fig. 1), which has
completed phase II clinical trials for melanoma, pancreatic,
lung and ovarian cancers.11 Unfortunately, the results were
mixed leading to reformulation. Nevertheless, other related
complexes have subsequently been developed,12,13 including
platinum bis-capronate (CT-47518) and platinum bis-butyrate
(CT-47463), which have improved stability profiles in human
plasma compared to the parent compound.14
A significant step forward in the field came in the form of
compounds that do not primarily target DNA, with trans-[tetra-
chlorobis(1H-indazole)ruthenate(III)], KP1019, its sodium salt
NKP-1339 and trans-[tetrachloro(dimethylsulfoxide)(imidazole)-
ruthenate(III)], NAMI-A (Fig. 2)15,16 being prominent examples
of compounds that preferentially target other biomolecules.
Although developed without a specific target in mind their
conception did follow a prominent rule, i.e. slow ligand
exchange kinetics, with that of Ru(III) complexes not being too
dissimilar to Pt(II) compounds.17 Both these compounds are
not particularly cytotoxic to cancer cells and in general are
much less cytotoxic than cisplatin.18,19 Thus, the notion that
the selection of drug candidates should be based on cytotoxi-
city studies was shown to be only partially valid and other cel-
lular assays could be equally, if not more, valuable.20
Moreover, while both these Ru(III) complexes can bind to DNA,
such binding is not believed to be relevant to their biological
action, raising the question of the bias in the field towards
DNA damaging agents. Compounds that target DNA, a ubiqui-
tous target present in diseased and healthy cells, tend to be
more systemically toxic than those with cancer-specific targets.
When cisplatin was introduced into the clinic, acceptable
therapeutic windows were narrower than those required today.
Hence, today drugs that interact with cancer-specific targets
should potentially provide more interesting therapies. This
rationale does not negate approaches to selectively deliver cis-
platin to the tumour site or the application of cisplatin pro-
drugs that only release cisplatin where needed21 and
lipoplatin, a liposomal formulation of cisplatin, is in a
number of advanced clinical trials.22
The problem of following rules is exemplified by Ru(II)
arene complexes, although it should be noted that to date
none have entered clinical trials (a Ru(II) polypyridyl photo-
sensitizer has apparently entered clinical trials).23 The low tox-
icity of Ru(III) complexes has been attributed, in part, to the
ability of Ru(III) to mimic iron binding to serum proteins,24,25
which should increase the amount of compound that reaches
cancer cells compared to healthy cells as the former tend to
have higher levels of transferrin receptors on their membrane.
However, this mechanism of drug delivery remains conten-
tious, with recent studies suggesting albumin-mediated trans-
Fig. 2 Structures of (from the left) KP1019 and NAMI-A.
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port mechanisms due to the thermodynamically more stable
complexes that tend to be formed with this protein.26 Cell
uptake is a critical factor in activity, with the higher cytotoxi-
city of KP1019 compared to NAMI-A attributed to more
complex entering the cells, which has been proposed to
involve both passive diﬀusion27 and transferrin-dependent
mechanisms.28 It has also been proposed that following cellu-
lar uptake Ru(III) complexes are activated by reduction to Ru(II)
complexes,29 a process more pronounced in the hypoxic
environment of tumour cells, thus oﬀering selectivity and pre-
sumably lowering toxicity. There is recently published evidence
to indicate that such a mechanism of activation may not take
place.27 Nevertheless, the mechanisms mentioned above
seemed, at the time, to justify the selection of Ru(III) anticancer
compounds over Ru(II), which presumably would be unstable
in a physiological environment due to ligand exchange kine-
tics and also would have higher general toxicities. However,
these hypotheses were incorrect and there is now a vast body
of data which show Ru(II) arene compounds have many ideal
properties for the treatment of diﬀerent cancers.30 Certainly,
several Ru(II) arene complexes are very cytotoxic, equivalent or
more cytotoxic than cisplatin, and lack the ability to dis-
tinguish between cancerous and healthy cells leading to high
general toxicity in vivo and presumably limited therapeutic
applications.31 However, other Ru(II) arene complexes not only
appear to be non-toxic, but they display unique antitumour
properties.32
Ru(II) arene complexes incorporating the amphiphilic 1,3,5-
triaza-7-phosphaadamantane (pta) ligand, i.e. Ru(η6-toluene)-
(pta)Cl2, RAPTA-T, and Ru(η6-p-cymene)(pta)Cl2, RAPTA-C
(Fig. 3), display very low toxicity in vivo and are not cytotoxic,
but do have relevant antitumour properties. Instead of target-
ing DNA, RAPTA-C binds to the histone protein core in chro-
matin.33 Binding follows aquation of the chloride ligands and
translates to mild growth inhibition on primary tumours
in vivo.34 RAPTA-C also exerts a strong antiangiogenic eﬀect
in vivo35 and sections of primary tumours taken from treated
mice have significantly fewer blood vessels.33 Interestingly,
this activity is combined with antimetastatic activity,36 unlike
other antiangiogenic compounds which are also prometa-
static.37 The antiangiogenic and antimetastatic eﬀects appear
to be due to interactions with the cell membrane, with the
majority of the compound localising on the membrane and
relatively little entering the cell.38 The combined eﬀects of
RAPTA compounds appear to be unique and, importantly,
when applied in combinations with other drugs, RAPTA-C
leads to eﬃcient inhibition of tumour growth at very low drug
doses in the absence of toxic side eﬀects.39
Other Ru(II) complexes shown to have clinically interesting
properties include an organometallic ruthenium species
termed RDC11 (Fig. 3).40 This complex has been tested against
xenografted A2780 ovarian cancer cells or U87 glioblastoma
cells implanted into nude mice in both cases demonstrating a
45% smaller tumour volume compared to control mice and
similar tumour reduction compared to cisplatin, but with
fewer side eﬀects. The complex [Ru(η6-arene)(en)Cl]+ (en =
ethylenediamine, RAED-C, Fig. 3), in which the en ligand was
included in analogy to the two NH3 ligands in cisplatin, shows
promising anticancer properties in diﬀerent in vivo models.41
Many derivatives have since been studied, including ones
based on osmium, and some have been evaluated in vivo.42
Concepts related to the biochemistry
of cancer cells
Diﬀerences in the biochemistry of cancer cells can also be
exploited to achieve selective activation or targeting. In princi-
pal, the hypoxic environment of a tumour can be exploited to
selectively activate chemotherapeutics and based on this
feature a series of cobalt complexes were developed with cyto-
toxicity depending on a hypoxia-released nitrogen mustard
ligand (Fig. 4).43 The complex is administered as a prodrug
with the cytotoxic group coordinated to the metal. This work
shows the validity of metal drugs based on first row transition
metal complexes and ingeniously exploits the very diﬀerent
exchange kinetics of cobalt in its diﬀerent oxidation states
through an appreciation of the unique biochemical character-
istics of cancer cells. In a hypoxic environment, a one-electron
reduction of Co(III) to Co(II) takes place which facilitates the
Fig. 3 The structures of (from the left) RAPTA-T (top left), RAPTA-C
(top right), RDC11 (bottom left) and RAED-C (bottom right). RDC11 and
RAED-C are formulated as PF6
− salts.
Fig. 4 Examples of (from the left) a complex that releases a nitrogen
mustand ligand and a curcumin ligand in hypoxic cancer tissue. Both
complexes are formulated as ClO4
− salts.
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release of the toxic ligand.40 Related cobalt44 and copper45
complexes that are activated by reduction have been developed,
including very recently a Co(III) complex that releases a cur-
cumin ligand upon reduction in a hypoxic environment
(Fig. 4).46 It should be noted that a diverse range of curcumin-
containing metal complexes have been reported that exhibit
promising properties47 such as highly selective cytotoxicity to
cancer cells over non-tumourigenic cells.48
Interestingly, in vivo studies in which tumours were oxy-
genated via normalization with axitinib showed that the Ru(II)
arene compound, RAPTA-C, could inhibit tumour growth con-
siderably more eﬀectively than in a non-oxygen elevated
tumour and was even markedly more active than doxo-
rubicin.49 Since doxorubicin exhibits nanomolar levels of cyto-
toxicity on cancer cells, whereas RAPTA-C is essentially non-
toxic in vitro, this switch in activity is quite remarkable.
Cancer cells are frequently characterized by elevated gluta-
thione (GSH), glutathione transferase (GST) and gamma-
glutamyl transferase (γGT) levels, which are generally con-
sidered to deactivate drugs. Indeed, the eﬃcacy of cisplatin is
modulated by interactions with glutathione with conjugation
leading to eﬄux from cancer cells.50 However, GST and γGT
overexpression actually provides the opportunity to target
resistant tumours with GST and γGT-activated prodrugs, i.e.
GST catalysed β-elimination may be harnessed to release a
toxic drug molecule from a drug-glutathione conjugate.51 Such
a concept is currently showing much potential with 4-(N-(S-
glutathionylacetyl) amino) phenylarsenoxide (GSAO), a GST-
activated arsenic-based agent, and with S-dimethylarsino-
glutathione (dainaparsin), a γGT-activated arsenic-based
prodrug (Fig. 5). These compounds are active against chemo-
resistant tumours such as pancreatic cancer and are under-
going clinical trials.51,52 Arsenic trioxide is a highly toxic
compound that has been reintroduced into the clinic for the
treatment of a number of cancers including acute promyelocy-
tic leukemia when retinoid or anthracycline chemotherapy has
not been eﬀective, and multiple myeloma, chronic myelogen-
ous leukemia, and acute myelogenous leukemia.53 A range of
quite severe side-eﬀects, albeit manageable ones, occur in
patients treated with arsenic trioxide and more selective
derivatives would be advantageous.
As mentioned above, GSAO and darinaparsin are gluta-
thione-conjugated arsenic complexes both assessed in clinical
trials.54,55 A Phase I/II study showed that darinaparsin is well
tolerated56 and a subsequent Phase II eﬃcacy study showed
promising disease-dependant results with lymphoma,55
leading to orphan drug designation for peripheral T-cell lymo-
phoma.57 Darinaparsin is now being developed as both a
monotherapy and in combination therapy (registered as
NCT01139359) for T-cell lymphoma and as an oral formulation
against solid tumours (registered as NCT01139346). Contrary
to being eliminated from cancer cells, the modified GSH
ligand facilitates cancer cell selective uptake in a multi-step
process.51,58 First, the GSH conjugate of darinaparsin is pro-
cessed by the external γGT and dipeptidase to aﬀord dimethyl-
arsinocysteine. Subsequently, this species is imported into the
cell via cysteine transporters.59 Consequently, drug activity is
dependent on the expression and eﬃcacy of both the γGT and
cysteine importing systems.59 In certain tumour types, these
mechanisms are more active, such as pancreatic tumours
including those of the pancreatic duct, aﬀording a degree of
selectivity.60
The majority of recently approved organic drugs target
specific proteins that are over-expressed or even unique to
cancer cells.61 Similarly, the mechanisms of many metal-based
compounds are increasingly implicated with enzyme inhi-
bition.62 Auranofin (Fig. 6), a gold-based drug used occasion-
ally in the clinic in the treatment of rheumatoid arthritis, has
been shown to induce apoptosis in cisplatin-resistant cell
lines.63 The mechanism of auranofin has been studied and a
number of enzymatic targets have been implicated in its mode
of action61,64 However, it would appear that auranofin inhibits
most isolated enzymes to some extent, with inhibition concen-
trations typically in the high nanomolar to low micromolar
range. To some extent auranofin, and possibly most gold-
based drugs, can be classified as likely frequent hitters for
in vitro screens, i.e. inhibiting to some extent any target investi-
gated. A similar phenomenon has been observed for certain
organic compounds, which has been attributed to drug aggre-
gates causing a clinically irrelevant cytotoxicity as oppose to
the drug itself.65 Given the propensity of gold complexes to
aggregate via the formation of gold–gold interactions66 the
same rationale may apply.
Ascending the transition metal groups
Some examples of metal-based drugs comprising first row
transition metals were mentioned in the previous section andFig. 5 The structures of (from the left) GSAO and darinaparsin.
Fig. 6 The structure of auranoﬁn.
Perspective Dalton Transactions
3204 | Dalton Trans., 2016, 45, 3201–3209 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 5
/6
/2
01
9 
7:
57
:0
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
many more classes of such compounds could be envisaged.
The role of the metal in some drugs is not always to coordinate
to a specific biomolecular target such as DNA or a protein. An
example of such a compound undergoing clinical evaluation is
a palladium–porphyrin complex that acts as a photosensitizer.
The complex in question, TOOKAD-soluble (Fig. 7), has pro-
gressed to phase III clinical trials for the photodynamic treat-
ment of prostate cancer (registered as NCT01875393). The role
of the palladium ion in TOOKAD-soluble appears to be two-
fold, first, helping to provide the ideal photophysical pro-
perties to the porphyrin and, second, being suﬃciently inert
so as not to be displaced during therapy.
Photodynamic therapy focusses drug toxicity in the tumour
environment by administering a photosensitizer that is acti-
vated by light – with the tumour environment being selectively
illuminated. Under irradiation with the appropriate wave-
length of light the photosensitizer reacts with oxygen to gene-
rate reactive oxygen species (ROS) that modulate the function
of surrounding tissue, leading to various responses according
to the level of ROS, but typically damaging blood vessels and
causing them to close, thereby shutting oﬀ the supply of nutri-
ents to a tumour.67 Singlet oxygen was initially thought critical
for the PDT eﬀect,68 but attributing the photodynamic eﬀect
exclusively to singlet oxygen may have been an oversimplifica-
tion. Recent clinical studies demonstrate eﬀective PDT using
TOOKAD-soluble as the photosensitizer in the absence of
singlet oxygen generation.69 Instead, the mechanism hinges
on the production of hydroxyl radicals in the vascular system
feeding the tumour tissue. Nevertheless, the net result is vas-
cular shutdown which isolates the cancer and leads to cell
death. Other possible mechanisms of Pd-containing porphyr-
ins depend on the compartmentalisation of the photosensiti-
ser, e.g. in the mitochondrial outer membrane70 or the
endoplasmic reticulum (ER),71 with compartmentalisation
depending on both the nature of the photosensitiser and the
time between administration of this complex and treatment.
Photosenstisers have been coupled to known anticancer
drug complexes such as cisplatin or oxaliplatin.72 The rationale
for this approach is to combine the cytotoxicity of platinum-
based drugs with PDT to reduce the amount of platinum drug
administered for an eﬀective dose, thereby reducing side
eﬀects. Co-administration may also overcome some types of
drug resistance and further developments involve tethering
PDT agents to other metal drugs such as those based on
ruthenium.73
Combination therapies are used to provide stronger thera-
pies for aggressive cancers and also to broaden the spectrum
of activity of drugs and a well-established combination therapy
comprises the application of cisplatin with radiotherapy. The
rationale behind this particular combination is that heavy
metal ions absorb X-rays more eﬃciently than biological
tissues leading to the release of low energy electrons to give
focussed treatments around the heavy metal centre.74
However, radiation damage to surrounding healthy tissue is
frequently observed in patients that undergo this combination
therapy. Drugs initially designed to treat radiation sickness,
i.e. for use in the event of a nuclear catastrophe could be co-
administered with cisplatin when used in combination with
radiotherapy. Take, for example, the manganese porphyrin
compound AEOL-10150 (Fig. 7). This compound is an anti-
oxidant mimicking the catalytic site of superoxide dismutase.
Although the complex is not in itself an anticancer drug, it
could prove highly beneficial in anticancer combination thera-
pies, and represents an interesting area for future research.
AEOL-10150 is already in clinical trials for a number of dis-
eases linked to oxidation damage, such as amyotropic lateral
sclerosis and spinal cord injury, and if applied with cisplatin–
radiotherapy combinations could reduce oxidative damage to
health tissue.75 Indeed, many porphyrin complexes
containing first row transition metal are under evaluation as
catalytic antioxidants for the treatment of many diﬀerent types
of diseases.76
Outlook
Cisplatin is a broad acting anticancer drug used to treat a
multitude of diﬀerent cancers. One cannot overstate the
success of this compound. And yet the success of cisplatin has
certainly biased the screening of metal-based drugs towards
Fig. 7 The structure of (from the left) TOOKAD-soluble and AEOL-10150 (formulated as the chloride salt).
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compounds that are active against many cancer types, often
with little thought as to which types or even sub-types of cancers
may be relevant. Such an approach, when successful, un-
doubtedly aﬀords a drug that helps a large number of patients.
However, such an approach is highly risky and, not surprisingly,
few new metal-based anticancer drugs have reached the clinic.
The development of therapies that are eﬀective on a small
subset of cancers, and that target specific abnormalities in
these cancers, potentially represents a more successful route
and in the future should lead to new drugs that induce a greater
tumour response for individual patients. Hence, designing
drugs based on cancer biology of specific tumour types, while
not ignoring the basic inorganic/organometallic chemistry
involved, could improve the drug development process.
New drugs that target specific abnormalities of certain
tumours, whether a general phenomenon, such as hypoxia, or
a single biomolecular target, such as a unique enzyme, could
increasingly be based on less toxic metals or even metals that
are essential to living systems. For catalytically active metal-
based drugs, first row transition metals should be less gene-
rally toxic and also tend to display superior catalytic activities.
Furthermore, if a metal complex is designed with a specific
three-dimensional shape that interacts selectively with an
enzyme and the metal itself is not reactive, it follows that non-
toxic metal centres would be advantageous, assuming they
aﬀord inert compounds.77 Rational drug design in organic
chemistry focuses on shape and often is inspired by nature.
Similarly, medicinal inorganic chemists could do the same. As
pointed out by others,78 the synthesis of transition metal com-
plexes with complex three dimensional structures is often
more facile than that of organic molecules and, if combined
with suitable electronic and/or ligand exchange properties,
may lead to new drugs that inhibit so called undruggable
targets such as transcription factors and non-enzymatic pro-
teins including scaﬀolds.79
In the clinic, most chemotherapeutic regimens used to
treat cancer involve the application of drug combinations with
each drug targeting a specific pathway or process. In the recent
phase I/II clinical trial of NAMI-A the ruthenium compound
was applied together with gemcitabine on patients with non-
small cell lung cancer.80 Unfortunately, convincing eﬃcacy
results were not obtained and the likelihood of further clinical
studies of NAMI-A are uncertain. NAMI-A was not specifically
designed for application in this type of cancer which could
have led to the poor outcome and the specific drug combi-
nation was chosen based on complementary mechanisms.
Finding synergistic drug combinations is clearly critical and a
highly challenging procedure, often relying on data from prior
clinical studies. Alternative methods, such as a phenotypic-
based feedback system control approach, i.e. high-throughput
cytotoxicity screening combined with a mathematical model
that reduces the number of experiments required, has been
used on RAPTA-C with a series of antiangiogenic agents.39 All
the resulting drug combinations that showed synergies con-
tained RAPTA-C and the in vitro data was subsequently vali-
dated in vivo. This and related strategies may facilitate the
process of finding synergistic drug combinations and should
improve the chances of a positive outcome of metal-based
drugs in phase II clinical studies, which are often based on
drug combinations comprising the new compound with an
established drug. Moreover, combinations that include broad
acting compounds, such as platinum-based compounds, are
increasingly likely to employ macroscopic drug delivery
systems that help to target the compound to the tumour. Deliv-
ery systems include the liposomal formulation of cisplatin
mentioned earlier, but increasingly more sophisticated
systems that target tumours via cancer selective compounds or
exploit natural delivery systems are being developed.81
In conclusion, it could be argued that the rules used to
guide the design of metal-based drugs are entirely valid and
should be followed, since the drugs that have made it into the
clinic to date follow these rules. However, there are numerous
examples of compounds which have been studied on advanced
pre-clinical models or are currently undergoing clinical trials,
e.g. the arsenic–glutathione prodrugs that target certain
tumours as well as others described above, to suggest we
should not be inhibited by these rules. There is clearly a long
way to go before we can say that certain classes of metal com-
plexes should be excluded from medicinal inorganic chemistry
and a better understanding of biology and the use of assays
other than cytotoxicity screening are essential to guide metal-
based drug design in the future.
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